Research development of postoperative intravesical chemotherapy for upper tract urothelial carcinoma
10.3760/cma.j.cn112330-20200228-00135
- VernacularTitle:上尿路尿路上皮癌术后膀胱灌注化疗的研究进展
- Author:
Duo ZHENG
1
;
Junyao LIU
;
Zhongjin YUE
;
Panfeng SHANG
Author Information
1. 兰州大学第二医院泌尿外科 兰州大学第二医院泌尿外科研究所 甘肃省泌尿系统疾病研究重点实验室 730030（工作单位为兰州大学第一医院泌尿外科 730000）
- From:
Chinese Journal of Urology
2020;41(5):397-400
- CountryChina
- Language:Chinese
-
Abstract:
Radical nephroureterectomy with bladder cuff resection is the gold standard for the treatment of high-grade upper tract urothelial carcinoma. Due to the multicenter characteristics of urothelial carcinoma, 22% to 47% of patients still have bladder tumor recurrence after operation. A series of randomized controlled trials have shown that postoperative intravesical chemotherapy can effectively reduce the intravesical recurrence rate after operation. At present, postoperative intravesical instillation treatment and drugs still refer to bladder urothelial carcinoma, and the standard treatment has not been established yet. This article reviews the relevant literature in recent years, and systematically discusses the research development of postoperative intravesical chemotherapy in terms of the choice of chemotherapy protocol and drugs.
